Eugene J Schaefer

US Patent:

20210246188, Aug 12, 2021

Filed:

Nov 25, 2020

Appl. No.:

17/105358

Inventors:

- Princeton NJ, US
Eugene J. Schaefer - Westfield NJ, US
Ronald Charles Bates - Irvine CA, US
Elizabeth A. Bramhall - Groton MA, US
David Michael Didio - Syracuse NY, US
Robert Donaldson - Southborough MA, US
Alan R. Flesher - Lawrenceville NJ, US
Helen Gray Haggerty - Manlius NY, US
David Henry Kirkley - East Syracuse NY, US
John Malcolm Tabor - Syracuse NY, US
Lee K. Tay - Princeton Junction NJ, US
Pallaiah Thammana - Manlius NY, US
Ajoy Velayudhan - Cary NC, US
David Edward Smolin - Pennington NJ, US
Reb J. Russell - Doylestown PA, US
Thomas James Vanden Boom - Flemington NJ, US
Dean Woodrow Brownell - Oswego NY, US
Jeffrey Schrimsher - Hillsborough NC, US
Joyce Patricia Whitehead - Manlius NY, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 14/705
A61K 38/19
C07K 16/28

Abstract:

The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

US Patent:

20200017569, Jan 16, 2020

Filed:

Jul 24, 2018

Appl. No.:

16/044252

Inventors:

- Princeton NJ, US
Eugene J. Schaefer - Westfield NJ, US
Ronald Charles Bates - Irvine CA, US
Elizabeth A. Bramhall - Groton MA, US
David Michael Didio - Syracuse NY, US
Robert Donaldson - Southborough MA, US
Alan R. Flesher - Lawrenceville NJ, US
Helen Gray Haggerty - Manlius NY, US
David Henry Kirkley - East Syracuse NY, US
John Malcolm Tabor - Syracuse NY, US
Lee K. Tay - Princeton Junction NJ, US
Pallaiah Thammana - Manlius NY, US
Ajoy Velayudhan - Cary NC, US
David Edward Smolin - Pennington NJ, US
Reb J. Russell - Doylestown PA, US
Thomas James Vanden Boom - Flemington NJ, US
Dean Woodrow Brownell - Oswego NY, US
Jeffrey Schrimsher - Hillsborough NC, US
Joyce Patricia Whitehead - Manlius NY, US

International Classification:

C07K 14/705
A61K 38/19
C07K 16/28
A61K 38/00
B01D 15/38

Abstract:

The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

US Patent:

20190092835, Mar 28, 2019

Filed:

Jul 24, 2018

Appl. No.:

16/044217

Inventors:

- Princeton NJ, US
Eugene J. Schaefer - Westfield NJ, US
Ronald Charles Bates - Irvine CA, US
Elizabeth A. Bramhall - Groton MA, US
David Michael Didio - Syracuse NY, US
Robert Donaldson - Southborough MA, US
Alan R. Flesher - Lawrenceville NJ, US
Helen Gray Haggerty - Manlius NY, US
David Henry Kirkley - East Syracuse NY, US
John Malcolm Tabor - Syracuse NY, US
Lee K. Tay - Princeton Junction NJ, US
Pallaiah Thammana - Manlius NY, US
Ajoy Velayudhan - Cary NC, US
David Edward Smolin - Pennington NJ, US
Reb J. Russell - Doylestown PA, US
Thomas James Vanden Boom - Flemington NJ, US
Dean Woodrow Brownell - Oswego NY, US
Jeffrey Schrimsher - Hillsborough NC, US
Joyce Patricia Whitehead - Manlius NY, US

International Classification:

C07K 14/705
C07K 16/28
A61K 38/19
A61K 38/00
B01D 15/38

Abstract:

The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

US Patent:

20190062399, Feb 28, 2019

Filed:

Jul 23, 2018

Appl. No.:

16/042977

Inventors:

- Princeton NJ, US
Eugene J. Schaefer - Westfield NJ, US
Ronald Charles Bates - Irvine CA, US
Elizabeth A. Bramhall - Groton MA, US
David Michael Didio - Syracuse NY, US
Robert Donaldson - Southborough MA, US
Alan R. Flesher - Lawrenceville NJ, US
Helen Gray Haggerty - Manlius NY, US
David Henry Kirkley - East Syracuse NY, US
John Malcolm Tabor - Syracuse NY, US
Lee K. Tay - Princeton Junction NJ, US
Pallaiah Thammana - Manlius NY, US
Ajoy Velayudhan - Cary NC, US
David Edward Smolin - Pennington NJ, US
Reb J. Russell - Doylestown PA, US
Thomas James Vanden Boom - Flemington NJ, US
Dean Woodrow Brownell - Oswego NY, US
Jeffrey Schrimsher - Hillsborough NC, US
Joyce Patricia Whitehead - Manlius NY, US

International Classification:

C07K 14/705
C07K 16/28
A61K 38/19
A61K 38/00
B01D 15/38

Abstract:

The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

US Patent:

20160237149, Aug 18, 2016

Filed:

Dec 23, 2015

Appl. No.:

14/757691

Inventors:

- Horsham PA, US
- Leiden, NL
Francis Maslanka - Malvern PA, US
Franciscus Johannes Ignatius Nagel - Leiden, NL
James Ryland - Malvern PA, US
Eugene Schaefer - Malvern PA, US

International Classification:

C07K 16/24

Abstract:

Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.

US Patent:

20140273092, Sep 18, 2014

Filed:

Mar 13, 2014

Appl. No.:

14/207915

Inventors:

- Leiden, NL
- Horsham PA, US
Francis Maslanka - Malvern PA, US
Franciscus Johannes Ignatius Nagel - Leiden, NL
James Ryland - Malvern PA, US
Eugene Schaefer - Malvern PA, US

Assignee:

Janssen Biologics B.V. - Leiden
Janssen Biotech, Inc. - Horsham PA

International Classification:

C07K 16/24

US Classification:

435 696

Abstract:

Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.